Journal of Neuro-Oncology

, Volume 101, Issue 3, pp 457–462 | Cite as

Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma

  • François Ducray
  • Monica Sierra del Rio
  • Catherine Carpentier
  • Dimitri Psimaras
  • Ahmed Idbaih
  • Caroline Dehais
  • Gentian Kaloshi
  • Karima Mokhtari
  • Sophie Taillibert
  • Florence Laigle-Donadey
  • Antonio Omuro
  • Marc Sanson
  • Jean-Yves Delattre
  • Khê Hoang-Xuan
Clinical Study – Patient Study

Abstract

Keywords

Oligodendroglioma Oligoastrocytoma Chemotherapy Radiotherapy Temozolomide Elderly 

References

  1. 1.
    Werner MH, Phuphanich S, Lyman GH (1995) The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer 76:1634–1642CrossRefPubMedGoogle Scholar
  2. 2.
    Fleury A, Menegoz F, Grosclaude P et al (1997) Descriptive epidemiology of cerebral gliomas in France. Cancer 79:1195–1202CrossRefPubMedGoogle Scholar
  3. 3.
    Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535CrossRefPubMedGoogle Scholar
  4. 4.
    Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588CrossRefPubMedGoogle Scholar
  5. 5.
    Combs SE, Wagner J, Bischof M et al (2008) Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 70:987–992CrossRefPubMedGoogle Scholar
  6. 6.
    Brandes AA, Monfardini S (2003) The treatment of elderly patients with high-grade gliomas. Semin Oncol 30:58–62CrossRefPubMedGoogle Scholar
  7. 7.
    Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214CrossRefPubMedGoogle Scholar
  8. 8.
    Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266CrossRefPubMedGoogle Scholar
  9. 9.
    Laigle-Donadey F, Figarella-Branger D, Chinot O et al (2010) Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol. doi:10.1007/s11060-009-0110-3
  10. 10.
    Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323–331CrossRefPubMedGoogle Scholar
  11. 11.
    Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC (2006) Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 24:1246–1252CrossRefPubMedGoogle Scholar
  12. 12.
    Ducray F, El Hallani S, Idbaih A (2009) Diagnostic and prognostic markers in gliomas. Curr Opin Oncol 21:537–542CrossRefPubMedGoogle Scholar
  13. 13.
    Brandes AA, Tosoni A, Cavallo G (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to emozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24:4746–4753CrossRefPubMedGoogle Scholar
  14. 14.
    Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714CrossRefPubMedGoogle Scholar
  15. 15.
    Abrey LE, Louis DN, Paleologos N et al (2007) Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 9:314–318CrossRefPubMedGoogle Scholar
  16. 16.
    van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722CrossRefPubMedGoogle Scholar
  17. 17.
    Wick W, Hartmann C, Engel C, Stoffels M et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880CrossRefPubMedGoogle Scholar
  18. 18.
    Dehais C, Laigle-Donadey F, Marie Y et al (2006) Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107:1891–1897CrossRefPubMedGoogle Scholar
  19. 19.
    Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154CrossRefPubMedGoogle Scholar
  20. 20.
    Chahlavi A, Kanner A, Peereboom D et al (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267–273CrossRefPubMedGoogle Scholar
  21. 21.
    Glass J, Hochberg FH, Gruber ML et al (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76:741–745CrossRefPubMedGoogle Scholar
  22. 22.
    Paleologos NA, Macdonald DR, Vick NA et al (1999) Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53:1141–1143PubMedGoogle Scholar
  23. 23.
    Taliansky-Aronov A, Bokstein F, Lavon I et al (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79:153–157CrossRefPubMedGoogle Scholar
  24. 24.
    Grant R, Liang BC, Page MA et al (1995) Age influences chemotherapy response in astrocytomas. Neurology 45:929–933PubMedGoogle Scholar
  25. 25.
    Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRefPubMedGoogle Scholar
  26. 26.
    Tortosa A, Vinolas N, Villa S et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071CrossRefPubMedGoogle Scholar
  27. 27.
    van den Bent MJ, Dubbink HJ, Sanson M et al (2009) MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 27:5881–5886CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • François Ducray
    • 1
    • 2
  • Monica Sierra del Rio
    • 1
  • Catherine Carpentier
    • 2
  • Dimitri Psimaras
    • 1
  • Ahmed Idbaih
    • 1
    • 2
  • Caroline Dehais
    • 1
  • Gentian Kaloshi
    • 1
  • Karima Mokhtari
    • 2
    • 3
  • Sophie Taillibert
    • 1
  • Florence Laigle-Donadey
    • 1
  • Antonio Omuro
    • 1
  • Marc Sanson
    • 1
    • 2
  • Jean-Yves Delattre
    • 1
    • 2
  • Khê Hoang-Xuan
    • 1
    • 2
    • 4
  1. 1.AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Hôpital de la SalpêtrièreParisFrance
  2. 2.Centre de Recherche de l’Institut du Cerveau et de la Moëlle Épinière (CRICM) UMR-S975Université Pierre et Marie Curie-Paris 6ParisFrance
  3. 3.AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuropathologie (K.M.)ParisFrance
  4. 4.AP-HP, Department of Neurology Mazarin, Groupe Hospitalier Pitié-SalpêtrièreParisFrance

Personalised recommendations